L
Lyric Pharmaceuticals
Clinical stage company developing novel gastrointestinal therapeutics for unmet medical needs in the hospital setting
About Lyric Pharmaceuticals
Lyric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company established in 2013, with a focus on developing treatments for gastrointestinal (GI) indications, particularly for unmet needs in the hospital and intensive care unit (ICU) settings. The company was co-founded by biopharma veterans Dr. David Wurtman, who serves as President and CEO, and Dr. M. Scott Harris, the Chief Medical Officer. The founding journey began when Dr. Harris, with prior experience as CMO at Avaxia Biologics, identified a key opportunity in the GI space and approached Dr. Wurtman. Together, they targeted a specific disease area and in-licensed their initial development candidate in September 2014.
The company's business model is centered on the clinical development and eventual commercialization of novel therapeutics. Its primary clients are critically ill patients within hospital ICUs. Lyric operates by raising capital from venture partners to fund multi-phase clinical trials required for drug approval. The company secured initial seed funding of $825,000 in 2014, led by RiverVest Venture Partners. This was followed by a significant Series A financing round, ultimately totaling $27.6 million by 2017, with lead investors including RiverVest Venture Partners, Sante Ventures, and Third Point Ventures.
Lyric's lead product candidate is LP-101, also known as ulimorelin, an intravenous ghrelin agonist. Ghrelin is often called the "feeding hormone," and agonists like ulimorelin are designed to offer both gastrointestinal pro-motility and pro-metabolic effects. LP-101 was specifically developed to treat Enteral Feeding Intolerance (EFI), a common and acute disorder of gastric motor function in critically ill, tube-fed patients that is associated with significant morbidity and mortality. In January 2018, the U.S. FDA granted Fast Track designation for the investigation of ulimorelin for EFI, highlighting the significant unmet medical need as no drug is currently approved for this condition. By March 2018, the company had completed enrollment for its Phase 2 PROMOTE study, an international, multicenter trial for LP-101. Prior to this, the drug had been administered to over 1,000 patients and volunteers with a favorable safety profile. However, as of early 2021, reports indicated that development for nutrition disorders had not progressed beyond Phase 2, and development for other conditions like gastroparesis and cachexia was discontinued. Some data sources now classify the company as deadpooled.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Feb 2015 | $20M | $82M | RiverVest Venture Partners · Aperture Venture Partners · Third Point Ventures · Sante Ventures | — |
Growth signals
Latest recorded traffic for Lyric Pharmaceuticals is 0 monthly website visits, down 100% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Lyric Pharmaceuticals in the San Francisco ecosystem
The Lyric Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
RiverVest Venture Partners
Third Point Ventures- APAperture Venture Partners
Sante Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lyric Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lyric Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










